The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial.

OBJECTIVE To determine if a human fibroblast-derived dermal substitute could promote the healing of diabetic foot ulcers. RESEARCH DESIGN AND METHODS A randomized, controlled, multicenter study was undertaken at 35 centers throughout the U.S. and enrolled 314 patients to evaluate complete wound closure by 12 weeks. Patients were randomized to either the Dermagraft treatment group or control (conventional therapy). Except for the application of Dermagraft, treatment of study ulcers was identical for patients in both groups. All patients received pressure-reducing footwear and were allowed to be ambulatory during the study. RESULTS The results demonstrated that patients with chronic diabetic foot ulcers of >6 weeks duration experienced a significant clinical benefit when treated with Dermagraft versus patients treated with conventional therapy alone. With regard to complete wound closure by week 12, 30.0% (39 of 130) of Dermagraft patients healed compared with 18.3% (21 of 115) of control patients (P = 0.023). The overall incidence of adverse events was similar for both the Dermagraft and control groups, but the Dermagraft group experienced significantly fewer ulcer-related adverse events. CONCLUSIONS The data from this study show that Dermagraft is a safe and effective treatment for chronic diabetic foot ulcers.

[1]  Modulation of Interferon‐Gamma Response by Dermal Fibroblast Extracellular Matrix , 2002, Annals of the New York Academy of Sciences.

[2]  David G Armstrong,et al.  Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. , 2001, Diabetes care.

[3]  B. Sheeman,et al.  Human three‐dimensional fibroblast cultures express angiogenic activity , 2000, Journal of cellular physiology.

[4]  R. Sibbald,et al.  High bacterial load in asymptomatic diabetic patients with neurotrophic ulcers retards wound healing after application of Dermagraft. , 2001, Ostomy/wound management.

[5]  J. Hansbrough,et al.  Fibroblast sheets enable epithelialization of sounds that do not support keratinocyte migration. , 1999, Tissue engineering.

[6]  L. Sanders,et al.  Diabetes mellitus. Prevention of amputation. , 1994, Journal of the American Podiatric Medical Association.

[7]  A. Hansson,et al.  Inhibited proliferation of fibroblasts derived from chronic diabetic wounds and normal dermal fibroblasts treated with high glucose is associated with increased formation of L‐lactate , 1998, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[8]  M. Levin.  Prevention and treatment of diabetic foot wounds. , 1998, Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society.

[9]  E. Middelkoop,et al.  Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. , 1998, The Journal of investigative dermatology.

[10]  D. M. Cooper,et al.  Definitions and guidelines for assessment of wounds and evaluation of healing. , 1994, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[11]  Z. Bloomgarden,et al.  American Diabetes Association 60th Scientific Sessions, 2000: the diabetic foot. , 2001, Diabetes care.

[12]  G. Oster,et al.  Potential Economic Benefits of Lower-Extremity Amputation Prevention Strategies in Diabetes , 1998, Diabetes Care.

[13]  G. Naughton,et al.  A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. , 2008, Artificial organs.

[14]  J. Hanft,et al.  Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. , 2002, The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons.

[15]  B. Gilchrest,et al.  Experimental approaches to chronic wounds , 1995, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[16]  D. Steed.  Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. , 1995, Journal of vascular surgery.

[17]  V. Falanga.  Classifications for wound bed preparation and stimulation of chronic wounds , 2000, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[18]  G. Reiber,et al.  Lower extremity foot ulcers and amputations in diabetes , 1995 .